Scarica l'app Stockscreener
0.00
100.00%
-0.2075
Dopo l'orario di chiusura:
.28
0.28
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.2075
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$4.26M
Reddito:
$31.56M
Utile/perdita netta:
$-46.89M
Rapporto P/E:
0.00
EPS:
-3.0329
Flusso di cassa netto:
$-26.70M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$3.09
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Nome
Casi Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare CASI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.00 | 4.26M | 31.56M | -46.89M | -26.70M | -3.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Iniziato | Mizuho | Buy |
| 2020-10-23 | Iniziato | Oppenheimer | Outperform |
| 2016-09-22 | Iniziato | Maxim Group | Buy |
| 2015-10-29 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Casi Pharmaceuticals Inc Borsa (CASI) Ultime notizie
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? - Stocktwits
CASI Pharmaceuticals Director Resigns but Stays On as Consultant - TipRanks
CASI Pharmaceuticals (CASI) director Barbara Krebs-Pohl exits board, to consult - Stock Titan
CASI Pharmaceuticals Company Profile & Introduction - Moomoo
MSN Money - MSN
CASIF Stock: Wang Chunhua COO Option Filing May 22, 2026 - Meyka
CASI Pharmaceuticals (CASIF) Revenue BreakdownMain Composition - Moomoo
CASI Pharmaceuticals (CASI) holder reports 58.8% stake and $5M note - Stock Titan
CASI Pharmaceuticals Receives FDA Clearance On The Investigation - GuruFocus
CASI Pharmaceuticals (CASI) posts 2025 loss and flags going‑concern risk - Stock Titan
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
CASIF Stock: Wang Chunhua COO Option Grant May 13, 2026 - Meyka
Number of shareholders of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
TradingKey - TradingKey
CASI Pharmaceuticals Inc. (CASIF) Cash From Financing (TTM) - Zacks Investment Research
CASIF Stock: Wang Chunhua COO Option Filing May 08, 2026 - Meyka
CASIF Stock: Wang Chunhua COO Option Filing May 05, 2026 - Meyka
CASI Pharmaceuticals Inc. (CASIF) Ps Ratio (TTM) - Zacks Investment Research
CASIF Stock: Wang Chunhua COO Option Filing May 01, 2026 - Meyka
CASIF Insider Filing: Wang Chunhua COO Option Grant April 2026 - Meyka
CASI Pharmaceuticals to be delisted from Nasdaq, shares to move to OTC market - MSN
CASI Pharmaceuticals (CASI) director reports fully vested option stakes - Stock Titan
CASIF Officer Wang Chunhua Files Initial Ownership, April 2026 - Meyka
CASI Pharmaceuticals Delays Annual 20-F Filing - TipRanks
Director Zeng lists CASI Pharmaceuticals (CASIF) fully vested option holdings - Stock Titan
CASI Pharmaceuticals Reshapes Medical Leadership Amid U.S. Streamlining Drive - TipRanks
CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP - marketscreener.com
Leadership shift at CASI (NASDAQ: CASI) as Global CMO role ends - Stock Titan
CASI Pharmaceuticals Closes Final US$5 Million Tranche of US$20 Million Convertible Notes - TipRanks
CASI Pharmaceuticals (OTCQB: CASIF) completes final $5M convertible note - Stock Titan
Hai Huang Net Worth (2026) - GuruFocus
Kun Qian Net Worth (2026) - GuruFocus
Chunhua Wang Net Worth (2026) - GuruFocus
Wei R Gao Net Worth (2026) - GuruFocus
CASIF Insider Trade: Wang Chunhua COO Option Filing April 2026 - Meyka
CASI (CASIF) General Counsel discloses vested and performance-based stock options - Stock Titan
CASI Pharmaceuticals Begins Trading on OTCQB Under Ticker CASIF - TipRanks
CASI Pharmaceuticals (CASI) begins OTCQB trading of ordinary shares as CASIF - Stock Titan
CASI Pharmaceuticals (OTC: CASIF) controller reports multiple stock option grants - Stock Titan
CASIF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CASI Pharmaceuticals (CASIF) executive details 2034 stock option positions - Stock Titan
[Form 3] CASI Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CASI Pharmaceuticals (CASIF) CMO holds 116,333 fully vested options at $1.93 - Stock Titan
CASIF: CASI Pharmaceuticals Inc.Comparison to Industry - Zacks Investment Research
All News for CASIF : CASI Pharmaceuticals Inc. - Zacks Investment Research
CASI SEC FilingsCasi Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CASI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Dividend HistoryCASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
Aug Wrap: Can CASI Pharmaceuticals Inc maintain its current growth rate2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Casi Pharmaceuticals Inc Azioni (CASI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):